HealthDay - THURSDAY, Sept. 18 (HealthDay News) -- The anti-cancer drug trabectedinshows promise in treating women with recurrent ovarian cancer, accordingto a study led by researchers at the University of California, Irvine.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.